ATE347910T1 - Zusammensetzungen zur behandlung von ischamischem gewebe - Google Patents

Zusammensetzungen zur behandlung von ischamischem gewebe

Info

Publication number
ATE347910T1
ATE347910T1 AT96936690T AT96936690T ATE347910T1 AT E347910 T1 ATE347910 T1 AT E347910T1 AT 96936690 T AT96936690 T AT 96936690T AT 96936690 T AT96936690 T AT 96936690T AT E347910 T1 ATE347910 T1 AT E347910T1
Authority
AT
Austria
Prior art keywords
tissue
ischemia
ischemic
treating
isamic
Prior art date
Application number
AT96936690T
Other languages
English (en)
Inventor
Jeffrey M Isner
Original Assignee
St Elizabeth S Medical Ct Of B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24178424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE347910(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by St Elizabeth S Medical Ct Of B filed Critical St Elizabeth S Medical Ct Of B
Application granted granted Critical
Publication of ATE347910T1 publication Critical patent/ATE347910T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Laser Surgery Devices (AREA)
  • Steroid Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AT96936690T 1995-10-20 1996-10-18 Zusammensetzungen zur behandlung von ischamischem gewebe ATE347910T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/545,998 US6121246A (en) 1995-10-20 1995-10-20 Method for treating ischemic tissue

Publications (1)

Publication Number Publication Date
ATE347910T1 true ATE347910T1 (de) 2007-01-15

Family

ID=24178424

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96936690T ATE347910T1 (de) 1995-10-20 1996-10-18 Zusammensetzungen zur behandlung von ischamischem gewebe
AT05270064T ATE419014T1 (de) 1995-10-20 1996-10-18 Verbindungen zur behandlung der ischaemischen gewebe

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05270064T ATE419014T1 (de) 1995-10-20 1996-10-18 Verbindungen zur behandlung der ischaemischen gewebe

Country Status (8)

Country Link
US (1) US6121246A (de)
EP (2) EP0883343B1 (de)
JP (3) JPH11514366A (de)
AT (2) ATE347910T1 (de)
AU (1) AU725290B2 (de)
CA (1) CA2235372C (de)
DE (2) DE69637800D1 (de)
WO (1) WO1997014307A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
AU7404994A (en) * 1993-07-30 1995-02-28 Regents Of The University Of California, The Endocardial infusion catheter
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
JPH09510093A (ja) 1994-03-08 1997-10-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮細胞増殖因子２
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7109308B1 (en) * 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
ES2240999T3 (es) * 1995-08-29 2005-10-16 Anges Mg, Inc. Medicamento que contiene un gen del hgf.
IL125756A (en) 1996-02-15 2003-05-29 Biosense Inc Catheter for use in surgery
US20080305999A1 (en) * 1996-11-01 2008-12-11 John Francis Martin Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
IL131021A0 (en) * 1997-01-29 2001-01-28 Cornell Res Foundation Inc Multiple site delivery of adenoviral vector for the induction of angiogenesis
WO1998039035A1 (en) * 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
DE69821011T3 (de) * 1997-10-02 2009-01-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
JP2001525173A (ja) * 1997-12-04 2001-12-11 ジェンザイム・コーポレーション 遺伝子発現を誘導するための組成物および方法
DE69838526T2 (de) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
WO2000029361A1 (en) 1998-11-13 2000-05-25 Daikin Industries, Ltd. Azeotropic composition comprising 1,1,1,3,3-pentafluoropropane and 1,1,1-trifluoro-3-chloro-2-propene, method of separation and purification of the same, and process for producing 1,1,1,3,3-pentafluoropropane and 1,1,1-trifluoro-3-chloro-2-propene
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
EP1016726A1 (de) * 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6440945B1 (en) * 1999-05-27 2002-08-27 Instituto Dermopatico Dell'immacolata Method of inducing angiogenesis in nonis chemic skeletal muscle
US20030236214A1 (en) * 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
EP1067190A1 (de) * 1999-07-09 2001-01-10 Introgene B.V. Gentherapie zur Erhöhung und/oder Induktion der Angiogenese
CA2348906A1 (en) * 1999-09-21 2001-03-29 Ryuichi Morishita Gene therapy for cerebrovascular disorders
CA2354029C (en) 1999-10-08 2012-01-10 Medgene Bioscience, Inc. Gene therapy for cardiomyopathy
CN1182874C (zh) * 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
US6748258B1 (en) * 1999-11-05 2004-06-08 Scimed Life Systems, Inc. Method and devices for heart treatment
US6329348B1 (en) 1999-11-08 2001-12-11 Cornell Research Foundation, Inc. Method of inducing angiogenesis
US20040072785A1 (en) * 1999-11-23 2004-04-15 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
US7105168B1 (en) 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
US6930089B2 (en) 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
AU6633801A (en) 2000-06-27 2002-01-08 Medgene Bioscience Inc Medicinal compositions for angiogenic therapy
MXPA02003434A (es) * 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
JPWO2002031138A1 (ja) * 2000-10-06 2004-02-19 株式会社ディナベック研究所 骨格筋に外来遺伝子を導入するためのパラミクソウイルスベクター
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
EP1330252A4 (de) * 2000-11-01 2007-12-26 Ludwig Inst Cancer Res In-vivo-stimulierung der angiogenen aktivität
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
ES2305138T3 (es) * 2000-11-27 2008-11-01 Dnavec Research Inc. Vector de paramixovirus que codifica factor 2 de crecimiento de fibroblastos (fgf2) y uso del mismo.
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20020168739A1 (en) * 2001-03-09 2002-11-14 Wu Kenneth K. Vectors, compositions and methods for treating a vascular disorder
US20020131959A1 (en) * 2001-03-14 2002-09-19 Ivo Buschmann Means and methods for the modulation of arteriogenesis
US20020192688A1 (en) * 2001-04-05 2002-12-19 Xiaoming Yang Imaging nucleic acid delivery
DK1385864T3 (da) * 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
WO2002083849A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7182944B2 (en) * 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
DE10122855A1 (de) * 2001-05-11 2002-11-14 Max Planck Gesellschaft Mittel zur Verbesserung der Gewebepenetration
US7709450B2 (en) * 2001-06-20 2010-05-04 Ludwig Institute For Cancer Research Stimulation of vascularization with VEGF-B-186
AU2002331669A1 (en) * 2001-08-23 2003-03-10 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
US20040031067A1 (en) * 2001-10-11 2004-02-12 Meenhard Herlyn Regulation of human skin healing
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US6817068B2 (en) * 2003-01-02 2004-11-16 The Burton Corporation Adjustable length strap assembly
WO2004098534A2 (en) * 2003-02-24 2004-11-18 Therion Biologics Corporation Methods for delivering angiogenic modulators using pox viruses
WO2004081040A2 (en) * 2003-03-12 2004-09-23 Advisys, Inc. Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications
WO2004087063A2 (en) * 2003-03-27 2004-10-14 Janssen Pharmaceutica Nv Use of erythropoietin in stroke recovery
BRPI0410844A (pt) * 2003-06-05 2006-06-27 Centelion fator de crescimento de fibroblasto de codificação de plasmìdeo para o tratamento de defeitos angiogênicos associados com hipercolesterolemia ou diabetes
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
WO2008058942A2 (en) 2006-11-13 2008-05-22 Charite - Universitätsmedezin Berlin Method of cell culture and method of treatment comprising a vepo protein variant
CA2682469A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall
CA2709398C (en) 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
CA2720611C (en) * 2008-04-09 2016-07-12 Viromed Co., Ltd. Lyophilized dna formulations for enhanced expression of plasmid dna
AU2010286511B2 (en) 2009-08-28 2016-05-26 Juventas Therapeutics, Inc. SDF-1 delivery for treating ischemic tissue
ES2549460T3 (es) * 2009-11-03 2015-10-28 F. Hoffmann-La Roche Ag NT-pro ANP y sFlt-1 para la diferenciación entre los eventos isquémicos y circulatorios
US10149864B2 (en) 2013-03-13 2018-12-11 The University Of Queensland Method of isolating cells for therapy and prophylaxis
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
US11554179B2 (en) 2018-07-19 2023-01-17 Helixmith Co., Ltd Lyophilized pharmaceutical compositions for naked DNA gene therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE165516T1 (de) * 1989-03-21 1998-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0591408A4 (en) * 1991-06-28 1996-11-27 Univ Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
EP0957172B1 (de) * 1992-11-18 2005-10-19 Arch Development Corporation Adenovirus-gelenkter Gen-Transfer zum Herz-und glatten vaskulären Muskel
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
JPH08508511A (ja) * 1993-04-29 1996-09-10 ワシントン・ユニバーシテイー 副行循環の改善への血小板由来成長因子の使用
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy

Also Published As

Publication number Publication date
AU7454896A (en) 1997-05-07
DE69636764D1 (de) 2007-01-25
CA2235372A1 (en) 1997-04-24
AU725290B2 (en) 2000-10-12
EP1625858A1 (de) 2006-02-15
EP0883343A4 (de) 2002-04-10
WO1997014307A1 (en) 1997-04-24
ATE419014T1 (de) 2009-01-15
JP2008024718A (ja) 2008-02-07
EP0883343B1 (de) 2006-12-13
DE69636764T2 (de) 2007-10-31
JPH11514366A (ja) 1999-12-07
EP1625858B1 (de) 2008-12-31
CA2235372C (en) 2009-01-27
EP0883343A1 (de) 1998-12-16
US6121246A (en) 2000-09-19
JP2011219502A (ja) 2011-11-04
DE69637800D1 (de) 2009-02-12

Similar Documents

Publication Publication Date Title
ATE347910T1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
DE69523074D1 (de) Verfahren zur behandlung von implantierbaren biologischen geweben zur verringerung von verkalkung
ATE145564T1 (de) Anordnung zur bestrahlung von laserstrahlen
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
EA199801044A1 (ru) Модуляторы регенерации тканей
BR9915573A (pt) Processo de preparação de uma composição protéica e uma fórmula infantil contendo a mesma
DE69434431D1 (de) Methoden zur behandlung von muskelerkrankungen und muskelstörungen
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
FI900808A0 (fi) Humant mannos bindande protein.
MXPA04004609A (es) Composicion que comprende y metodo para utilizar angptl3 de proteina 3 como angiopoyetina.
DE69032200D1 (de) Verfahren zur Behandlung von Schnittblumen
DE69025922D1 (de) Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
ATE407677T1 (de) Gereinigte zubereitungen von 10-propargyl-10- deazaaminopterin und verfahren zu ihrer verwendung in der tumorbehandlung
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
ATE308563T1 (de) Aktives hedgehog-protein-konjugat, verfahren zur herstellung und verwendung
EA200001124A1 (ru) Способ генной терапии
DE69607034D1 (de) Pcna bindende substanz
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
Szent-Györgyi et al. Fixation of muscle proteins with antibodies
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties